PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
This Phase 1 trial will evaluate the safety and tolerability of PSA-Activated PSA-PAH1 in subjects who have shown biochemical failure and have either completed at least one primary radiation therapy for prostate cancer and have evidence of recurrent local prostate cancer without metastases.
Prostate Cancer
DRUG: PSA-Activated PSA-PAH1
Safety and Tolerance of PSA-PAH1|MTD of PSA-PAH1
Pharmacokinetic data on PSA-PAH1|Immune response to PSA-PAH1|Evidence of activity of PSA-PAH1
For more information please contact Primary Investigator or Protox Therapeutics, Inc.